CD80-mediated induction of immunostimulation in two ocular melanoma cell lines is augmented by interferon-γ

Melanoma Research

Volumn 12, Issue 2, 2002, Pages 129-138

  Mulcahy, K A ^a   Alexander, S ^a   Platts, K E ^a   Wardle, C ^a   Sisley, K ^a   Rennie, I G ^a   Murray, A K ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

CD80; Immunostimulation; Interferon ; Melanoma

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON;

ARTICLE; CANCER CELL CULTURE; EYE CANCER; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD80; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; EYE NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNIZATION; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MELANOMA; MONOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0036247106     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200204000-00005     Document Type: Article

References (37)

1. Tumour antigens recognised by T lymphocytes
2. CD28/B7 system of T cell costimulation
3. A cell culture model for T lymphocyte clonal anergy
4. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
5. Costimulation of antitumour immunity by the B7 counterreceptor for T lymphocyte molecules CD28 and CTLA-4
6. + T cells by B7-transfected melanoma cells
7. Specificity and longevity of antitumour immune responses induced by B7-transfected tumours
8. Tumour immunogenicity determines the effect of B7 costimulation on T cell-mediated tumour immunity
9. + tumour cells are potent vaccines for stimulating tumour rejection in tumour-bearing mice
10. Antigenicity of human melanoma cells tranfected to express the B7-1 CO-stimulatory molecule (CD80) varies with the level of B7-1 expression
11. Enhancement of the anti-tumour immune response using a combination of interferon-γ and B7 expression in an experimental mammary carcinoma
12. Co-expression of B7-1 and ICAM-1 on tumours is required for rejection and the establishment of a memory response
13. B7-1 and interleukin 12 synergistically induce effective antitumour immunity
14. Tumour cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumour-specific immunity
15. Development of immunogenic colorectal cancer cell lines for vaccination: Expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro
16. Gene transfer of costimulatory molecules into a human colorectal cancer cell line: Requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity
17. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2
18. The expression of CD70 and CD80 by gene-modification tumor cells induces antitumor response depending on the MHC status
19. Restoration of alloreactivity of melanoma by transduction with B7.1
20. d-binding self-peptide p2Ca
21. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
22. Gene transfer of the CD80 costimulatory molecule into melanoma cells using a novel episomal vector
23. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients
24. Infrequent expression of the MAGE gene family in uveal melanomas
25. Recognition of melanoma-associated peptides by peripheral blood mononuclear cells of ocular melanoma patients
26. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma
27. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma
28. A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells - Monitoring the humoral immune response
29. Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma
30. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
31. Vaccination with IL-12 gene-modified autologous melanoma cells: Pre-clinical results and a first clinical phase I study
32. Gene therapy with autologous interleukin 2-secreting tumor cells in patients with malignant melanoma
33. HLA antigen expression on uveal melanoma cells in vivo and in vitro
34. + T lymphocytes with B7 and lymphocyte function-associated antigen-3 results in distinct cell activation profiles
35. B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells
36. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma
37. + T cell responses in antitumor immunity